Founder:

Dr. Guannan Wang, founder of VetOmics, brings over a decade of expertise in cancer genomics and precision medicine, and a strong commitment to advancing cancer care for companion animals.

During her time at the University of Pennsylvania and Vidium Animal Health, Dr. Wang played a key role in integrating genomic diagnostics into routine cancer care for dogs. She has led the development of cutting-edge genomic tools and precision oncology databases, and has personally overseen thousands of canine genomic reports.

Dr. Wang has contributed significantly to the field of canine cancer genomics, particularly in understanding the genomic drivers of hemangiosarcoma. She also led research that demonstrated the clinical utility of genomic testing in guiding treatment decisions, aiding-in diagnosis, and improving patient outcomes.

Together with her co-founder and a team of dedicated advisors, Dr. Wang founded VetOmics to deliver high-quality, high-actionability genomic tests, empowering veterinarians to offer the best possible care for pets fighting cancer.

Here is a list of Dr. Wang’s publications

Clinical, pathologic and molecular findings in 2 Rottweiler littermates with appendicular osteosarcoma. Res Sq. Preprint. 2024 Apr 11

Genomic analysis across 53 canine cancer types reveals novel mutations and high clinical actionability potential. Veterinary and Comparative Oncology, 2023 Dec 5. Corresponding author

Novel Genomic Prognostic Biomarkers for Canine Cancer Patients. Journal of Veterinary Internal Medicine, 2023 Oct 6. Corresponding author

Standing in the canine precision medicine knowledge gap: Improving annotation of canine cancer genomic biomarkers through systematic comparative analysis of human cancer mutations in COSMIC. Veterinary and Comparative Oncology, 2023 May 8. Corresponding author. See PDF here.

Genomic tumor analysis provides clinical guidance for the management of diagnostically challenging cancers in dogs. Journal of American Veterinary Medical Associations, 2023 Mar 1.

Canine Oncopanel: A capture-based, NGS platform for evaluating the mutational landscape and detecting putative driver mutations in canine cancers. Veterinary and Comparative Oncology, 2021 Jul 19. Corresponding author. See PDF here.

Molecular subtypes in canine hemangiosarcoma reveal similarities with human angiosarcoma. Plos One, 2020; 15(3): e0229728. Corresponding author

Actionable mutations in canien hemangiosarcoma. Plos One, 2017, Nov 30; 12(11): e0188667